FCF MedTech & Diagnostics Public Equity Monitor

The FCF MedTech & Diagnostics Public Equity Monitor, part of FCF Life Sciences Research Series, is the most detailed and comprehensive valuation analysis for med-tech and diagnostics companies in the micro, small and midcap market segment in Europe. It provides relevant valuation metrics (e.g. ratios, multiples), general information, performance data, analyst consensus and shareholder analysis as well as statistics by sector.

The following trends were noted over the past year:

  • Over the last year, the share price development of the European med-tech and diagnostics sector rose by +57% and +36%, respectively
  • The diagnostics sector recorded an average share price performance of +227% since beginning of this year (Virogates A/S, ANGLE plc, Immunodiagnostics Systems Holding PLC being the main drivers)
    • Companies from the med-tech and diagnostics sectors have almost doubled their share prices since the IPO with an average share price increase of approx. +115%
  • Analysts see an average upside potential of +49% in the share prices of the European med-tech and diagnostics sector
    • Integrum AB has recorded the highest share price performance with +754% within the last year, followed by ViroGates A/S with +237%, and NanoRepro AG with +204%

The selection of companies is based on the following criteria:

  • Companies operating in the med-tech or diagnostics sector
  • Headquarters located in Europe
  • Current market capitalization is between EUR 50 million and EUR 1 billion as to focus on the micro – mid cap market segment instead of the large / blue chip companies
  • Companies with a market capitalization below EUR 50m and above EUR 1 billion were excluded
  • FCF may add additional companies on its own discretion (regardless of market capitalization)

FCF MedTech & Diagnostics Public Equity Monitor

The following trends were noted over the past year:

  • Over the last year, the share price development of the European med-tech and diagnostics sector rose by +57% and +36%, respectively
  • The diagnostics sector recorded an average share price performance of +227% since beginning of this year (Virogates A/S, ANGLE plc, Immunodiagnostics Systems Holding PLC being the main drivers)
    • Companies from the med-tech and diagnostics sectors have almost doubled their share prices since the IPO with an average share price increase of approx. +115%
  • Analysts see an average upside potential of +49% in the share prices of the European med-tech and diagnostics sector
    • Integrum AB has recorded the highest share price performance with +754% within the last year, followed by ViroGates A/S with +237%, and NanoRepro AG with +204%

The selection of companies is based on the following criteria:

  • Companies operating in the med-tech or diagnostics sector
  • Headquarters located in Europe
  • Current market capitalization is between EUR 50 million and EUR 1 billion as to focus on the micro – mid cap market segment instead of the large / blue chip companies
  • Companies with a market capitalization below EUR 50m and above EUR 1 billion were excluded
  • FCF may add additional companies on its own discretion (regardless of market capitalization)

Quoted in the Press

Press Release

FCF Life Sciences in the Börse Online magazine | 19. April 2021

FCF Life Sciences in the Börse Online magazine | 19. April 2021 The Life Sciences team at FCF Fox Corporate Finance has recently published an analysis on Special Purpose Acquisition Companies (SPACs) with a focus on healthcare, among others, in the Börse Online magazine. The analysis includes the number and volume of healthcare SPAC IPOs to date, as well as the share price performance of healthcare companies already acquired by SPACs. FCF concludes that the companies’ stock prices have increased on average by 12% since the acquisition was announced. For more information, please check out the recently published FCF Life

Read More »
Press Release

FCF Life Sciences: Boom Bei Healthcare-SPACS Ungebrochen | GoingPublic 13.04.2021

Der Boom um Special Purpose Acquisition Companies, auch SPACs genannt, setzt sich 2021 ungebremst fort. Lag die Zahl der SPAC-Börsengänge im gesamten Jahr 2020 noch bei 306 SPAC-IPOs, liegt sie in den ersten drei Monaten dieses Jahres bereits bei 246. Von Dr. Mathias Schott und Alexander Kuhn „2021 wird das Jahr der SPACs. Gerade für kosten- und forschungsintensive Healthcare-Unternehmen bieten SPACs einen schnellen und effizienten Weg an die Börse und zu notwendiger Liquidität“, sagt Dr. Mathias Schott, Leiter von FCF Life Sciences. So steigt die Zahl der SPAC-Börsengänge mit Fokus auf den Healthcare-Bereich bereits jetzt sprunghaft an: Nach 78 IPOs

Read More »

RESEARCH

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:

Licensing

Recent licensing trends of European Biotech companies in China
Upcoming
Recent licensing trends of European Biotech companies in China
Upcoming

Biotech Licensing Monitor – China
-Upcoming-
Recent licensing trends of European Biotech companies in China

NEWS & PRESS

Scroll Up